查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1806286

全球 3D 列印药品市场（按 3D 列印技术、剂型、药物释放、治疗领域和最终用户）：预测（2025-2030 年）

3D Printed Drugs Market by 3D Printing Technology, Dosage Form, Drug Release, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

3D列印医药市场预计2024年将达到1.7843亿美元，2025年成长至2.0289亿美元，复合年增长率为14.44%，到2030年将达到4.0097亿美元。

主要市场统计数据
预测年份（2024年） 1.7843亿美元
基准年（2025年） 2.0289亿美元
预测年份（2030年） 4.0097亿美元
复合年增长率（%） 14.44%

详细了解技术创新、产业发展和策略机会，为 3D 列印药物奠定基础

3D列印正在彻底改变製药业，使其在药物开发和生产中实现了前所未有的客製化、精准化和速度。该技术突破了传统製造的限制，能够按需生产具有患者特定剂量、形状和释放曲线的复杂剂型。这种模式转移的驱动力源于硬体设计、新型可列印材料以及与传统品管和法律规范无缝整合的先进数位化工作流程的进步。

揭示由 3D 列印技术、不断变化的法规和协作生态系统动态推动的製药製造业的变革

随着3D列印从概念验证走向商业性化，製药业正在发生根本性的变化。首先，从批量生产到数位化生产的转变正在重新定义供应链架构。透过实现在地化、按需生产，製造商可以最大限度地缩短库存生命週期，降低物流复杂性，并透过针对个别患者量身定制精准剂量来减少浪费。

评估 2025 年美国关税对供应链弹性、成本结构和策略采购决策的累积影响

2025年美国新关税的实施可能对全球3D列印医药供应链产生重大影响。来自海外的原材料和专用聚合物的进口关税可能会提高，这将直接影响硬体製造商和製药公司的成本结构。为此，各企业正在评估替代筹资策略，并考虑为关键零件采购资源，以保持营运弹性。

3D 列印医药市场动态的关键细分洞察，涵盖技术方法、剂型、释放特性、治疗领域和最终用户

3D列印医药市场的特点是技术方法多样，以满足不同的临床需求和生产规模。积层製造流程涵盖从基于喷嘴和颗粒的熔融沉积建模喷墨和选择性雷射烧结，以及高解析度光固化成形法平台。每种方法在分辨率、材料相容性和产量之间实现了不同的平衡，使开发人员能够选择最适合特定剂量设计的方法。

战略区域分析重点关注美洲、中东和非洲以及亚太地区的成长动力和市场特征

区域动态将在塑造3D列印药物的采用和创新轨迹方面发挥关键作用。在美洲，对数位基础设施和支持性法律规范的大量投资正在加速试验计画和商业性落地。领先的製药公司和研究机构正在紧密合作，将开创性的配方转化为患者可用的产品。

详细了解透过创新、协作和策略经营模式塑造 3D 列印製药产业的主要企业

3D列印製药领域的产业领导者以其对专有硬体平台、新型可列印聚合物和整合数位生态系统的投入而闻名。专注于高解析度立体光固化成形法的公司正在与材料科学公司建立策略合作关係，以开发符合严格监管标准的生物相容性树脂。其他公司则专注于透过与聚合物製造商合作，扩大熔融沈积成型的规模，以扩展其载药丝材库。

产业领导者应采取指南，加速 3D 列印药物的采用，并克服监管、营运和伙伴关係的挑战

寻求利用 3D 列印製药技术的行业领导者必须采取多管齐下的策略，将创新与监管合规和卓越营运相结合。一个根本步骤是投资模组化硬体系统，以适应未来材料和设计的发展，从而确保长期灵活性。同时，他们必须与材料科学专家建立伙伴关係，共同开发针对特定治疗应用优化的生物相容性聚合物。

全面的调查方法，详细说明支持市场洞察的资料来源、分析框架和品质保证措施

本报告中所呈现的研究结果是基于严谨的调查方法，整合了原始资料和二手资料。原始研究包括对高阶主管、研发负责人、监管专家和最终用户代表的深入访谈，以获得关于技术采用、市场动态和营运挑战的第一手观点。这些质性见解也辅以各治疗领域主要应用计划的详细案例研究。

关于 3D 列印药物未来发展轨迹和产业演变的核心见解和观点的综合

3D列印药物的发展轨迹标誌着技术创新、不断发展的法律规范以及策略合作的融合，这些因素共同预示着个人化医疗新时代的到来。积层製造已证明其能够解决药物配方、供应链灵活性和患者依从性等长期挑战，同时也激发了新的治疗可能性。

目录

第一章 引言

第二章 分析方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 多重药物隔间列印整合技术可在单一药片中进行标靶联合治疗
  • 利用生物列印技术按需製造载药组织支架
  • 实施数位供应链平台，确保3D列印药品的可追溯性
  • 不断发展的法规结构，旨在解决大规模采用药品印刷的品质和安全标准
  • 针对儿童和老年人的客製化剂量列印的出现，以优化弱势群体的药物动力学
  • 将智慧感测器介面应用于 3D 列印平板电脑，即时监测患者遵从性
  • 基于区块链的数位供应链平台实现3D列印药品的端到端可追溯性

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：美国关税的累积影响（2025年）

8. 3D列印药品市场（依3D列印技术）

  • 熔融沈积成型
    • 喷嘴底座
    • 颗粒基
  • 喷墨列印
  • 选择性雷射烧结
  • 立体光刻技术

第 9 章：3D 列印药物市场（按剂型）

  • 胶囊
  • 奈米粒子
  • 药片

第 10 章：3D 列印药品市场（按药物释放）

  • 控释
  • 缓释性
  • 立即释放

第 11 章：3D 列印药品市场（依治疗领域）

  • 心血管系统
  • 牙科
  • 神经科
  • 瘤

第 12 章：3D 列印药品市场（依最终用户划分）

  • CRO（委外研发机构）
  • 医院和诊所
  • 製药公司
  • 研究所

13.美国3D列印药品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲3D列印药品市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15.亚太地区3D列印药品市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • 3D Systems, Inc.
    • Aprecia Pharmaceuticals, LLC
    • Anatomics Pty Ltd.
    • Curify Ltd
    • Cyfuse Biomedical KK
    • FabRx Ltd.
    • GlaxoSmithKline Plc
    • Laxxon Medical Corp.
    • MB Therapeutics
    • Merck KGaA
    • Proto Labs Inc.
    • Renishaw PLC
    • Siemens AG
    • Triastek, Inc.
    • Yissum

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-431C35F6C179

The 3D Printed Drugs Market was valued at USD 178.43 million in 2024 and is projected to grow to USD 202.89 million in 2025, with a CAGR of 14.44%, reaching USD 400.97 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 178.43 million
Estimated Year [2025] USD 202.89 million
Forecast Year [2030] USD 400.97 million
CAGR (%) 14.44%

Setting the Stage for 3D Printed Pharmaceuticals with an In-Depth Introduction to Technological Innovations, Industry Evolution, and Strategic Opportunities

3D printing is revolutionizing the pharmaceutical industry by enabling unprecedented levels of customization, precision, and speed in drug development and manufacturing. The technology transcends traditional production constraints by allowing on-demand fabrication of complex dosage forms with patient-specific dosing, shapes, and release profiles. This paradigm shift is fueled by advances in hardware design, novel printable materials, and sophisticated digital workflows that integrate seamlessly with conventional quality control and regulatory frameworks.

As stakeholders across the entire pharmaceutical value chain-from research laboratories to clinical settings-embrace additive manufacturing, the implications extend beyond novel product formats. Development timelines are being compressed through rapid prototyping, formulation screening, and iterative design. Manufacturing footprints are evolving to support decentralized production models that bring drug fabrication closer to the point of care. Meanwhile, emerging regulatory pathways are adapting to this disruptive technology, fostering an environment where safety and innovation coalesce.

This executive summary provides a concise yet comprehensive introduction to the drivers, opportunities, and challenges shaping the 3D printed drugs market. It captures the technological underpinnings, regulatory catalysts, and commercial imperatives that are steering transformative change. Decision-makers will find an authoritative overview designed to inform strategic planning, investment decisions, and collaborative initiatives in the pursuit of next-generation pharmaceutical solutions.

Unveiling Transformative Shifts in Pharmaceutical Manufacturing Driven by 3D Printing Technologies, Regulatory Evolutions, and Collaborative Ecosystem Dynamics

The pharmaceutical landscape is undergoing fundamental shifts as 3D printing moves from proof-of-concept to commercial viability. First, the transition from batch manufacturing to digital production is redefining supply chain architectures. By enabling localized and on-demand fabrication, manufacturers can minimize inventory lifecycles, reduce logistics complexities, and mitigate wastage through precise dosing tailored to individual patients.

Second, regulatory agencies have begun to establish frameworks that embrace additive processes. The introduction of guidelines addressing digital file integrity, material characterization, and process validation is streamlining approval pathways. This alignment between industry and regulators cultivates a fertile environment for innovation while safeguarding quality and patient safety.

Third, strategic collaborations among technology providers, pharmaceutical companies, and contract research organizations are accelerating translation from laboratory to clinic. Shared investments in research platforms, standardization efforts, and joint development agreements are unlocking synergies that amplify technological capabilities and market readiness.

Together, these dynamics are reshaping the pharmacological development continuum. Innovations in materials science, hardware engineering, and digital design converge with progressive regulatory approaches to produce a manufacturing paradigm that balances customization with scalability. As these transformative shifts unfold, stakeholders are well positioned to capitalize on the next frontier of personalized medicine.

Assessing the Cumulative Impact of United States Tariffs in 2025 on the Supply Chain Resilience, Cost Structures, and Strategic Sourcing Decisions

The imposition of new United States tariffs in 2025 is poised to exert significant influence on the global 3D printed drug supply chain. Raw materials and specialized polymers sourced from overseas may incur elevated import duties, directly impacting the cost structure for hardware manufacturers and pharmaceutical innovators alike. In response, organizations are evaluating alternative procurement strategies and considering reshoring critical components to maintain operational resilience.

Moreover, the increased financial burden is prompting stakeholders to revisit long-term sourcing partnerships. Collaborative relationships with domestic suppliers are being strengthened to hedge against volatility, while cross-border alliances are renegotiated to accommodate the revised tariff regime. Such adaptations are essential to preserving margins without compromising the robustness of material supply pipelines.

In parallel, the cost implications of tariffs are accelerating investments in process optimization. Manufacturers are exploring consolidation of material usage, recycling initiatives, and novel material formulations that deliver comparable performance at lower expense. Digital optimization tools, including predictive analytics and process monitoring, are being harnessed to maximize yield and minimize waste.

While the tariff landscape introduces new complexities, it also serves as a catalyst for strategic supply chain innovation. By proactively addressing the implications of policy shifts, industry players can fortify their resilience and secure a competitive edge in the evolving 3D printed drugs market.

Key Segmentation Insights into 3D Printed Drug Market Dynamics Spanning Technology Approaches, Dosage Forms, Release Profiles, Therapeutic Areas, and End Users

The 3D printed drug market is characterized by a diverse array of technological approaches that cater to distinct clinical requirements and manufacturing scales. Additive processes range from nozzle-based and pellet-based fused deposition modeling to inkjet and selective laser sintering, culminating in high-resolution stereolithography platforms. Each modality offers its own balance of resolution, material compatibility, and throughput, enabling developers to select the optimal method for specific dosage designs.

Beyond hardware, the spectrum of dosage forms has expanded to include traditional tablets, encapsulated solids, and cutting-edge nanoparticle constructs. These formats are engineered to enhance patient compliance, bioavailability, and therapeutic targeting. Meanwhile, the ability to tailor drug release profiles-controlled, delayed, or immediate-empowers formulators to optimize pharmacokinetics while reducing side effects.

Therapeutic applications traverse multiple medical disciplines. Cardiovascular, dental, neurology, and oncology treatments have all benefited from precision-fabricated dosage forms that address unique absorption and delivery challenges. End users such as contract research organizations, hospitals and clinics, pharmaceutical companies, and academic research institutes are collaborating to pioneer clinical validation and scale production.

By integrating technology, form factor, release mechanism, therapeutic focus, and end-user requirements, the market presents a nuanced landscape ripe for segmentation-driven growth. Companies that align their capabilities with these distinct vectors can unlock tailored solutions and capture specialized niches within the broader 3D printed drugs ecosystem.

Strategic Regional Analysis Highlighting Growth Drivers and Market Characteristics across the Americas, Europe Middle East and Africa, and Asia Pacific

Regional dynamics play a critical role in shaping the adoption and innovation trajectory of 3D printed pharmaceuticals. In the Americas, extensive investment in digital infrastructure and supportive regulatory frameworks have accelerated pilot programs and commercial launches. Leading pharmaceutical companies and research institutions collaborate closely to translate pioneering formulations into patient-ready products.

The Europe, Middle East and Africa region exhibits a complex tapestry of regulatory environments and healthcare priorities. Progressive policies in Western Europe are enabling clinical trials and early market entry, while emerging markets in the Middle East and Africa are gradually building capacity through public-private partnerships and targeted innovation incentives. This diversity fosters a dynamic landscape where regional centers of excellence co-exist with opportunities for market expansion.

In the Asia-Pacific region, rapid industrial growth and strong governmental backing for advanced manufacturing have positioned several nations at the forefront of additive pharmaceutical development. Significant R&D expenditure, coupled with a substantial generic drug manufacturing base, has catalyzed both homegrown and collaborative ventures. Stakeholders in this region are leveraging economies of scale to reduce costs and drive large-scale adoption of 3D printing technologies in clinical settings.

These regional nuances underscore the importance of tailored strategies that reflect local regulatory requirements, technological readiness, and healthcare priorities. Companies that adapt their market approaches accordingly are poised to capture growth in these geographically diverse markets.

In-Depth Examination of Key Companies Shaping the 3D Printed Pharmaceuticals Sector through Innovation, Collaborations, and Strategic Business Models

Industry leaders across the 3D printed pharmaceuticals space are distinguished by their investments in proprietary hardware platforms, novel printable polymers, and integrated digital ecosystems. Companies specializing in high-resolution stereolithography have established strategic collaborations with material science firms to develop biocompatible resins that meet stringent regulatory standards. Others have focused on scaling fused deposition modeling through partnerships with polymer manufacturers to expand the library of drug-loaded filaments.

Collaborative alliances between pharmaceutical giants and additive manufacturing pioneers have yielded joint development agreements that accelerate clinical validation pathways. These partnerships combine formulation expertise with cutting-edge printing technologies, facilitating the rapid translation of research-grade prototypes into scalable production lines. Licensing deals and co-development contracts have become pivotal mechanisms for sharing risk and maximizing market reach.

In addition, contract research organizations have carved out specialized service offerings that encompass formulation screening, process development, and regulatory support for 3D printed dosage forms. By embedding end-to-end capabilities, they serve as essential enablers for companies seeking to outsource critical development milestones. This convergence of capabilities is shaping a competitive landscape where collaboration, intellectual property differentiation, and service depth determine market leadership.

As the ecosystem continues to evolve, companies that balance technological innovation with robust business models and strategic partnerships will emerge as frontrunners in the 3D printed drugs domain.

Actionable Guidance for Industry Leaders to Drive 3D Printed Drug Adoption and Navigate Regulatory, Operational, and Partnership Challenges

Industry leaders seeking to capitalize on 3D printed drug technologies must adopt a multi-faceted strategy that aligns innovation with regulatory preparedness and operational excellence. A foundational step is to invest in modular hardware systems that can accommodate future material and design advancements, thereby safeguarding long-term flexibility. Concurrently, organizations should cultivate partnerships with material science experts to co-develop biocompatible polymers optimized for specific therapeutic applications.

Engagement with regulatory authorities is equally critical. Proactive dialogue and participation in standardization initiatives enable companies to influence emerging guidelines and anticipate compliance requirements. Embedding quality-by-design principles into digital workflows will streamline approval processes and reinforce product reliability.

Operational resilience demands a reassessment of supply chain risk profiles. Firms should diversify raw material sources, explore near-shoring opportunities, and implement digital tools for real-time monitoring of material integrity and production performance. Incorporating data analytics and predictive maintenance into manufacturing environments will further enhance continuity and cost efficiency.

Lastly, cultivating an ecosystem of academic collaborators, contract research organizations, and clinical partners will accelerate translational efforts. By orchestrating cross-disciplinary innovation networks, industry players can catalyze the adoption of 3D printed pharmaceuticals and drive sustainable growth in this transformative market.

Comprehensive Research Methodology Detailing Data Sources, Analytical Frameworks, and Quality Assurance Measures Underpinning the Market Insights

The findings presented in this report are grounded in a rigorous research methodology that integrates both primary and secondary data sources. Primary research involved in-depth interviews with senior executives, R&D heads, regulatory specialists, and end-user representatives to capture firsthand perspectives on technology adoption, market dynamics, and operational challenges. These qualitative insights were supplemented by detailed case studies of leading implementation projects across diverse therapeutic areas.

Secondary research encompassed analysis of regulatory filings, patent databases, industry white papers, and technical journals to map the evolution of additive manufacturing in pharmaceuticals. Publicly available information on collaborative agreements, clinical trial registries, and company disclosures provided additional context on strategic trends and competitive positioning.

Data triangulation techniques were employed to cross-verify insights, ensuring consistency and robustness of conclusions. Analytical frameworks focused on segmentation by technology, dosage form, release mechanism, therapeutic area, end user, and region. This multi-dimensional approach enabled the identification of nuanced growth drivers, barriers to entry, and emerging opportunities.

Quality assurance measures included peer reviews by subject matter experts and validation of key data points against multiple independent sources. This comprehensive methodology underpins the credibility of the report's insights, equipping decision-makers with an authoritative resource on the 3D printed drugs market.

Synthesizing Core Findings and Forward-Looking Perspectives on the Future Trajectory of 3D Printed Pharmaceuticals and Industry Evolution

The trajectory of 3D printed pharmaceuticals is characterized by converging technological innovation, evolving regulatory frameworks, and strategic collaborations that collectively promise a new era of personalized medicine. Additive manufacturing has demonstrated its capacity to address longstanding challenges in drug formulation, supply chain flexibility, and patient compliance, while also stimulating novel therapeutic possibilities.

Despite the transformative potential, stakeholders must navigate policy changes, cost considerations, and material development hurdles. The 2025 tariff environment underscores the importance of supply chain agility and the need for strategic sourcing partnerships. Moreover, the success of market adoption hinges on the harmonization of quality standards and regulatory alignment.

Looking ahead, continued investment in R&D, expansion of printable material libraries, and refinement of digital design tools will drive the next phase of growth. Regions that cultivate supportive ecosystems-combining regulatory clarity, academic-industry collaboration, and investment incentives-will emerge as global innovation hubs.

Ultimately, the maturation of the 3D printed drugs market will be shaped by the ability of industry leaders to translate technological breakthroughs into scalable, patient-centric solutions. With deliberate strategy, collaborative networks, and a proactive regulatory mindset, the promise of tailored, on-demand pharmaceuticals can be fully realized.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of multi-drug compartment printing enabling targeted combination therapies in single pills
  • 5.2. Adoption of bioprinting techniques for on-demand production of drug-loaded tissue scaffolds
  • 5.3. Implementation of digital supply chain platforms ensuring traceability of 3D printed pharmaceutical products
  • 5.4. Evolving regulatory frameworks addressing quality and safety standards for mass adoption of drug printing
  • 5.5. Emergence of pediatric and geriatric tailored dosage printing to optimize pharmacokinetics in vulnerable populations
  • 5.6. Application of smart sensor interfaces in 3D printed pills for real-time monitoring of patient adherence
  • 5.7. Blockchain-enabled digital supply chain platforms for end-to-end traceability of 3D printed medications

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. 3D Printed Drugs Market, by 3D Printing Technology

  • 8.1. Introduction
  • 8.2. Fused Deposition Modeling
    • 8.2.1. Nozzle-Based
    • 8.2.2. Pellet-Based
  • 8.3. Inkjet Printing
  • 8.4. Selective Laser Sintering
  • 8.5. Stereolithography

9. 3D Printed Drugs Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Capsules
  • 9.3. Nanoparticles
  • 9.4. Tablets

10. 3D Printed Drugs Market, by Drug Release

  • 10.1. Introduction
  • 10.2. Controlled Release
  • 10.3. Delayed Release
  • 10.4. Immediate Release

11. 3D Printed Drugs Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiovascular
  • 11.3. Dental
  • 11.4. Neurology
  • 11.5. Oncology

12. 3D Printed Drugs Market, by End User

  • 12.1. Introduction
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical Companies
  • 12.5. Research Institutes

13. Americas 3D Printed Drugs Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa 3D Printed Drugs Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific 3D Printed Drugs Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. 3D Systems, Inc.
    • 16.3.2. Aprecia Pharmaceuticals, LLC
    • 16.3.3. Anatomics Pty Ltd.
    • 16.3.4. Curify Ltd
    • 16.3.5. Cyfuse Biomedical K.K.
    • 16.3.6. FabRx Ltd.
    • 16.3.7. GlaxoSmithKline Plc
    • 16.3.8. Laxxon Medical Corp.
    • 16.3.9. MB Therapeutics
    • 16.3.10. Merck KGaA
    • 16.3.11. Proto Labs Inc.
    • 16.3.12. Renishaw PLC
    • 16.3.13. Siemens AG
    • 16.3.14. Triastek, Inc.
    • 16.3.15. Yissum

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. 3D PRINTED DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL 3D PRINTED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. 3D PRINTED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. 3D PRINTED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. 3D PRINTED DRUGS MARKET: RESEARCHAI
  • FIGURE 26. 3D PRINTED DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. 3D PRINTED DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 28. 3D PRINTED DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. 3D PRINTED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL 3D PRINTED DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL 3D PRINTED DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NOZZLE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NOZZLE-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PELLET-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PELLET-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY INKJET PRINTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY INKJET PRINTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY SELECTIVE LASER SINTERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY SELECTIVE LASER SINTERING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY STEREOLITHOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY STEREOLITHOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DELAYED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DELAYED RELEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DENTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DENTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 89. CANADA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 90. CANADA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 95. CANADA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 96. CANADA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 101. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 103. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 104. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 107. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 108. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 109. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 110. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 113. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 114. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 115. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 116. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 117. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 118. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 119. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 120. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 125. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 128. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 129. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 130. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 131. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 132. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED KINGDOM 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 167. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 168. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 169. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 170. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 171. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 172. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 173. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. GERMANY 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 175. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 179. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 180. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 181. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 182. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 183. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 184. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 185. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. FRANCE 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 191. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 192. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 193. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 194. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 195. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 196. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 197. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. RUSSIA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. ITALY 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. ITALY 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 203. ITALY 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 204. ITALY 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 205. ITALY 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 206. ITALY 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 207. ITALY 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 208. ITALY 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 209. ITALY 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. ITALY 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 211. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 213. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 214. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 215. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 216. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 217. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 218. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 219. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 220. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 221. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. SPAIN 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 238. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 240. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 242. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 244. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. SAUDI ARABIA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 250. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 252. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 254. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 256. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 257. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. SOUTH AFRICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 259. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 262. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 263. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 265. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 266. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 267. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 268. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 269. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. DENMARK 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 274. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 276. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 278. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 280. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. NETHERLANDS 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 283. QATAR 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. QATAR 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 285. QATAR 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 286. QATAR 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 287. QATAR 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 288. QATAR 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 289. QATAR 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 290. QATAR 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 291. QATAR 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 292. QATAR 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 293. QATAR 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. QATAR 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 297. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 298. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 299. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 300. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 301. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 302. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 303. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 304. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 305. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. FINLAND 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 309. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 310. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 311. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 312. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 313. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 314. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 315. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 316. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 317. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. SWEDEN 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 319. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 321. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 322. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 323. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 324. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 325. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 326. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 327. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 328. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 329. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NIGERIA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 331. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 333. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2024 (USD MILLION)
  • TABLE 334. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2025-2030 (USD MILLION)
  • TABLE 335. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 336. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 337. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2024 (USD MILLION)
  • TABLE 338. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025-2030 (USD MILLION)
  • TABLE 339. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 340. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 341. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. EGYPT 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)

TABLE